4th World Epigenetics Summit
|Event Date/Time: Dec 04, 2012||End Date/Time: Dec 06, 2012|
As the bridge between genotype and phenotype, the field of epigenetic research has enormous potential to progress diagnosis and therapy in oncology and the wider disease spectrum.
Are you prepared for the leap forward in epigenetic therapeutics?
Realizing such immense potential will require thought leaders to address very specific challenges. Calls to action are being made to identify and validate new epigenetic drug targets for oncological, autoimmune and inflammatory diseases. Industry and academia also agree that more must be done to productively integrate recent advances in the basic and clinical sciences.
With strong representation and candid discussion guaranteed from senior level figures at GSK, the Structural Genomics Consortium, Constellation Pharmaceuticals and Epizyme, the 4th World Epigenetics Summit will address these issues directly and deliver commercially directed insight into the most pressing technical and strategic issues at hand.
The 4th World Epigenetics Summit provides a unique platform on which senior representatives from GSK, Constellation and Epizyme share ideas with leading academic figures such as Tony Kouzarides and Chas Bountra. In bringing together the minds behind the most exciting drugs in development, the meeting represents two days dedicated to overcoming the most pressing challenges in epigenetic drug development.
â€¢ Get an up-to-the-minute snapshot of the very latest epigenetic target classes for disease therapy from Epizyme, GSK and Constellation Pharmaceuticals
â€¢ Learn how the SGC are driving innovation by open source chemical probe design
â€¢ Discover the excitement that epigenetic drugs are generating in the clinic with4SC
â€¢ Explore the potential of epigenetic modulation in non-oncological disease indications with GSK
â€¢ Get excited at the potential of RNA therapeutics in a range of disease indications with RaNA Therapeutics
â€¢ Find out how to optimize methods, assays and practices throughout the production pipeline so you can maximize the value of your R&D spend
Who should attend:
â€¢ Epigenetic drug developers looking to progress epigenetic drugs into the clinic and meet business leaders
â€¢ Pharma companies with a strong interest in epigenetic drug development
â€¢ Technology specialists seeking to highlight novel platforms, assays and equipment
â€¢ Business development professionals assessing pipeline investment opportunities
â€¢ Scientists and academics working in medicinal chemistry and the wider epigenetic spectrum